基因組學市場機會、成長要素、產業趨勢分析及2026-2035年預測。

2025 年全球基因組學市場價值 447 億美元，預計到 2035 年將以 15.6% 的複合年成長率成長至 1887 億美元。

基因組學產業正經歷著顯著的全球成長，其驅動力來自慢性病和遺傳性疾病盛行率的上升以及對精準醫療解決方案日益成長的需求。基因組學專注於對遺傳物質進行全面分析，以更深入地了解生物功能、疾病進展和個人化治療方案。定序技術、基因分析平台、人工智慧和生物資訊學的持續進步正在加速醫療保健和生命科學領域更精準、更有效率的基因組學應用的發展。隨著基因組學日益融入臨床診斷、治療方法開發、藥物研發和預防醫學，產業格局正在發生巨大變化。此外，基因組技術在疾病識別、治療最佳化和標靶治療的應用日益廣泛，也進一步推動了市場的擴張。產業相關人員正積極透過技術創新、基因組平台擴展以及在生物技術和醫療保健生態系統中建立策略性合作夥伴關係來提升自身能力。有利的監管支持和完善的報銷機制也推動了全球醫療系統和研究機構對基因組學解決方案的更廣泛應用。

預計到2025年，該產品細分市場將佔據66.9%的市場佔有率，到2035年將達到1,27億美元，2026年至2035年的複合年成長率（CAGR）為15.3%。此細分市場主要包括基因組分析儀器以及進行研究活動和診斷程序所必需的耗材。基因組儀器的技術進步顯著提高了運作效率、擴充性和分析準確性，從而促進了其在研究機構和臨床環境中的應用。耗材在該細分市場中仍然佔據重要佔有率，因為它們在基因組檢測和實驗室工作流程中重複使用。對可靠的基因組分析和大規模研究能力的日益成長的需求，進一步推動了該產品細分市場的成長。

預計到2025年，定序市場規模將達到170億美元。隨著技術創新不斷提升處理速度、準確性和整體成本效益，定序技術在市場擴張中持續發揮核心作用。先進的定序平台能夠以更高的準確性和通量進行大規模基因分析，從而支持科學研究和臨床領域的廣泛應用。定序技術在基因組全面評估和疾病相關分析的應用日益廣泛，這提升了其在醫療保健和生技產業的重要性。隨著技術的不斷進步和對高效基因組分析需求的不斷成長，預計定序市場在未來幾年將繼續保持強勁成長。

到2025年，北美基因組學市佔率將達到42.7%。該地區憑藉其先進的醫療保健基礎設施、對生物醫學研究的高度重視以及基因組學在臨床和科研領域日益廣泛的應用，將繼續保持主導地位。醫療保健投資的增加、生物技術活動的拓展以及有利於研究的環境，都推動了該地區市場的成長。對個人化治療方案、疾病早期檢測和先進診斷技術的需求不斷成長，也加速了基因組學在北美的普及應用。領先的基因組學創新者的存在，以及定序、診斷和生物資訊技術的持續進步，進一步提升了該地區市場的可及性和創新性。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 行業洞察

• 產業生態系分析
• 影響產業的因素
  • 促進因素
    • 遺傳性疾病和慢性病盛行率增加
    • DNA定序與基因編輯技術的進步
    • 精準醫療的廣泛應用
    • 政府在基因組研究上的努力與資金投入
  • 產業潛在風險與挑戰
    • 關於基因數據的倫理和隱私問題
    • 高成本和可負擔性方面的挑戰
  • 市場機遇
    • 開發經濟高效的快速定序技術
    • 將人工智慧和機器學習相結合，以推進基因組數據分析
• 成長潛力分析
• 技術展望
  • 目前技術
  • 新興技術
• 價格分析
• 監理情勢
• 波特的分析
• PESTLE分析
• 人工智慧和生成式人工智慧對市場的影響
• 未來市場趨勢

第4章 競爭情勢

• 介紹
• 企業市佔率分析
  • 世界
  • 北美洲
  • 歐洲
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係和聯盟
  • 新產品發布
  • 業務拓展計劃

第5章 市場估計與預測：依類型分類，2022-2035年

• 產品
  • 裝置
  • 耗材和試劑
• 服務
  • 基於NGS的服務
  • 核心基因組學服務
  • 生物標誌轉化服務
  • 計算服務
  • 其他服務

第6章 市場估計與預測：依技術分類，2022-2035年

• PCR（聚合酵素鏈鎖反應）
• 順序
• 微陣列
• 核酸萃取與純化
• 其他技術

第7章 市場估計與預測：依應用領域分類，2022-2035年

• 診斷
• 藥物發現和藥物開發
• 精準醫療
• 農業和畜牧業調查
• 其他用途

第8章 市場估算與預測：依最終用途分類，2022-2035年

• 醫院和診所
• 研究機構和學術/政府機構
• 製藥和生物技術公司
• 其他最終用戶

第9章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • UAE

第10章：公司簡介

• Agilent Technologies
• BGI Genomics
• Bio-Rad Laboratories
• Color Genomics
• Danaher
• Eppendorf
• Eurofins Scientific
• F. Hoffmann-La Roche
• Illumina
• Myriad Genetics
• NVIDIA
• Oxford Nanopore Technologies
• Pacific Biosciences of California
• QIAGEN
• Quest Diagnostics
• Thermo Fisher Scientific

The Global Genomics Market was valued at USD 44.7 billion in 2025 and is estimated to grow at a CAGR of 15.6% to reach USD 188.7 billion by 2035.

The genomics industry is witnessing substantial growth worldwide due to the increasing prevalence of chronic and inherited disorders, along with rising demand for precision-based healthcare solutions. Genomics focuses on the comprehensive analysis of genetic material to better understand biological functions, disease progression, and individualized therapeutic approaches. Continuous advancements in sequencing technologies, gene analysis platforms, artificial intelligence, and bioinformatics are accelerating the development of more accurate and efficient genomic applications across healthcare and life sciences. The growing integration of genomics into clinical diagnostics, therapeutic development, pharmaceutical research, and preventive healthcare is significantly transforming the industry landscape. In addition, the rising adoption of genomic technologies in disease identification, treatment optimization, and targeted medicine is supporting broader market expansion. Industry participants are actively strengthening their capabilities through technological innovation, expansion of genomic platforms, and strategic collaborations across biotechnology and healthcare ecosystems. Favorable regulatory support and improving reimbursement structures are also encouraging the wider implementation of genomics solutions across healthcare systems and research institutions globally.

The products segment accounted for 66.9% share in 2025 and is projected to reach USD 122.7 billion by 2035, growing at a CAGR of 15.3% 2026-2035. This segment primarily includes genomic instruments and consumable materials that are essential for conducting research activities and diagnostic procedures. Technological advancements in genomic equipment have significantly improved operational efficiency, scalability, and analytical accuracy, enabling greater adoption across research laboratories and clinical environments. Consumables continue to represent a critical portion of the segment due to their recurring use throughout genomic testing and laboratory workflows. Increasing demand for reliable genomic analysis and large-scale research capabilities is further driving growth within the products segment.

The sequencing segment generated USD 17 billion in 2025. Sequencing technologies continue to play a central role in market expansion as innovations improve processing speed, precision, and overall cost efficiency. Advanced sequencing platforms enable large-scale genetic analysis with enhanced accuracy and high-throughput capabilities, supporting wider application across research and clinical settings. The increasing use of sequencing technologies for comprehensive genomic evaluation and disease-related analysis is strengthening their importance across the healthcare and biotechnology industries. Ongoing technological progress and rising demand for efficient genomic interpretation are expected to sustain strong growth within the sequencing segment over the coming years.

North America Genomics Market held a 42.7% share in 2025. The region continues to maintain a leading position due to its advanced healthcare infrastructure, strong focus on biomedical research, and increasing implementation of genomics across clinical and scientific applications. Growing investments in precision healthcare initiatives, expanding biotechnology activities, and supportive research environments are contributing to regional market growth. Rising demand for personalized treatment approaches, early-stage disease identification, and advanced diagnostic technologies is also accelerating adoption throughout North America. The presence of major genomics innovators and continuous technological developments in sequencing, diagnostics, and bioinformatics are further enhancing accessibility and innovation across the regional market.

Key companies operating in the Global Genomics Market include Agilent Technologies, BGI Genomics, Bio-Rad Laboratories, Color Genomics, Danaher, Eppendorf, Eurofins Scientific, F. Hoffmann-La Roche, Illumina, Myriad Genetics, NVIDIA, Oxford Nanopore Technologies, Pacific Biosciences of California, QIAGEN, Quest Diagnostics, and Thermo Fisher Scientific. Companies operating in the Global Genomics Industry are adopting multiple strategic initiatives to strengthen their market position and expand their global presence. Leading players are heavily investing in research and development activities to introduce advanced sequencing systems, improved analytical software, and more efficient genomic testing solutions. Strategic partnerships with biotechnology firms, pharmaceutical companies, healthcare providers, and research organizations are helping companies accelerate innovation and broaden application areas. Market participants are also expanding their product portfolios through acquisitions and collaborations to enhance technological capabilities and improve service offerings. In addition, businesses are increasingly integrating artificial intelligence and data analytics into genomic platforms to improve data interpretation and operational efficiency. Several companies are focusing on geographic expansion, laboratory network development, and automation technologies to improve accessibility, streamline workflows, and strengthen long-term customer relationships across the global genomics market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Type trends
  • 2.2.3 Technology trends
  • 2.2.4 Application trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of genetic and chronic diseases
    • 3.2.1.2 Advancements in DNA sequencing and gene editing technologies
    • 3.2.1.3 Increasing adoption of precision medicine
    • 3.2.1.4 Government initiatives and funding for genomics research
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Ethical and privacy concerns around genetic data
    • 3.2.2.2 High cost and affordability issues
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of affordable and rapid sequencing technologies
    • 3.2.3.2 Integration of AI and machine learning for enhanced genomic data analysis
• 3.3 Growth potential analysis
• 3.4 Technology landscape
  • 3.4.1 Current technology
  • 3.4.2 Emerging technologies
• 3.5 Pricing Analysis (Driven by Primary Research)
• 3.6 Regulatory landscape (Driven by primary research)
  • 3.6.1 North America
  • 3.6.2 Europe
  • 3.6.3 Asia Pacific
  • 3.6.4 Latin America
  • 3.6.5 Middle East and Africa
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Impact of AI and generative AI on the market
• 3.10 Future market trends (Driven by primary research)

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Products
  • 5.2.1 Instruments
  • 5.2.2 Consumables and reagents
• 5.3 Services
  • 5.3.1 NGS-based services
  • 5.3.2 Core genomics services
  • 5.3.3 Biomarker translation services
  • 5.3.4 Computational services
  • 5.3.5 Other services

Chapter 6 Market Estimates and Forecast, By Technology, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 PCR (polymerase chain reaction)
• 6.3 Sequencing
• 6.4 Microarray
• 6.5 Nucleic acid extraction and purification
• 6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Diagnostics
• 7.3 Drug discovery and development
• 7.4 Precision medicine
• 7.5 Agriculture and animal research
• 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Research centers and academic and government institutes
• 8.4 Pharmaceutical and biotechnology companies
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Agilent Technologies
• 10.2 BGI Genomics
• 10.3 Bio-Rad Laboratories
• 10.4 Color Genomics
• 10.5 Danaher
• 10.6 Eppendorf
• 10.7 Eurofins Scientific
• 10.8 F. Hoffmann-La Roche
• 10.9 Illumina
• 10.10 Myriad Genetics
• 10.11 NVIDIA
• 10.12 Oxford Nanopore Technologies
• 10.13 Pacific Biosciences of California
• 10.14 QIAGEN
• 10.15 Quest Diagnostics
• 10.16 Thermo Fisher Scientific